{"entity":{"id":"nct05141149","kind":"trial","name":"First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Prestige Biopharma Limited, active and no longer recruiting.","summary":"First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05141149 by Prestige Biopharma Limited, with 80 participants enrolled, started 2023-06-05 and due to reach its primary completion in 2026-07. Interventions recorded: PBP1510 (400mg/16mL) and Gemcitabine (1000 mg/m^2).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05141149","url":"https://clinicaltrials.gov/study/NCT05141149"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05141149","phase":"1/2","setting":"A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer","sponsor":"Prestige Biopharma Limited","enrolled":80,"outcomes":[]},"route":"/trials/nct05141149/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"pbp1510","kind":"drug","name":"PBP1510","route":"/drugs/pbp1510/"}]}}